2Sant M,Allemani C,Berrino F,et al.Breast cancer survival in Europe and the United States[J].Cancer,2004,100(8):715-722.
3Olsen AH,Njor S,Vejborg W,et al.Breast cancer mortality in Copenhagen after introduction of mammography screening cohort study[J].BMJ,2005,330(5):220-222.
4Christiane K K,Simone S,Claudia CL,et al.Mammography,breast ultrasound,and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer[J].J Clin Oncol,2005,23(33):8469-8476.
5Anne A T,Liliane O,Carl EK,et al.Monitoring therapeutic efficacy in breast carcinomas[J].Eur Radiol,2006,11(16):2549-2558.
6吴炅.乳腺癌前哨淋巴结活检[M].上海:上海科学技术出版社,2005:192-197.
7乳腺癌临床实践指南(中国版).www.nccn.org.
8于泳,方志沂.乳腺原位癌[J].北京:北京大学医学出版社,2005:137-138.
9Chan KC,Knox WF,Sinha G,et al.Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ[J].Cancer,2001,91(1):9-16.
5The ATAC (Arimidex,Tamoxifen Aone or in Combination) Trialist's Group.Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:first results of the ATAC randomized trial[J].Lancet,2002,359 (9324):2131-2139.
6Goss PE,Ingle JN,Martino S,et al.Randomized placebo-controlled trail of letrozole in postmenopausal women with early breast cancer copleting five years of tamoxifen[J].Breast Cancer Res Treat,2003,82(Supple 1):42.
7Coombes RC,Hall E,Gibson LJ,et al.A randomized trail of exmeatane after two to three years of tamoxfen therapy in postmenopausal women with primary breast cancer[J].N Eng J Med,2004,350 (11):1081-1092.
8Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,2002. CA Cancer J Clin, 2005, 55:74-108.
9Parkin DM, Whelan SL, Ferlay J, et al. Cancer in five continents.Vol Ⅷ. IARC scientific publication No. 155. Lyon: IARC Press,2002. 212-231.
10Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med, 2000, 19 :335 -351.
